294 related articles for article (PubMed ID: 35933942)
1. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
[TBL] [Abstract][Full Text] [Related]
2. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder.
Murphy SM; Polsky D; Lee JD; Friedmann PD; Kinlock TW; Nunes EV; Bonnie RJ; Gordon M; Chen DT; Boney TY; O'Brien CP
Addiction; 2017 Aug; 112(8):1440-1450. PubMed ID: 28239984
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
Farabee D; Condon T; Hallgren KA; McCrady B
J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis.
Murphy SM; Jeng PJ; McCollister KE; Leff JA; Jalali A; Shulman M; Lee JD; Nunes EV; Novo P; Rotrosen J; Schackman BR
Addiction; 2021 Dec; 116(12):3444-3453. PubMed ID: 33950535
[TBL] [Abstract][Full Text] [Related]
6. Extended release injectable naltrexone before vs. after release: A randomized trial of opioid addicted persons who are in prison.
Woody GE; Poole S; Yu E; Carroll J; Lynch KG
J Subst Abuse Treat; 2021 Aug; 127():108355. PubMed ID: 34134881
[TBL] [Abstract][Full Text] [Related]
7. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
[TBL] [Abstract][Full Text] [Related]
8. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community: Results of a Double-Blind, Placebo-Controlled Randomized Trial.
Springer SA; Di Paola A; Azar MM; Barbour R; Biondi BE; Desabrais M; Lincoln T; Skiest DJ; Altice FL
J Acquir Immune Defic Syndr; 2018 May; 78(1):43-53. PubMed ID: 29373393
[TBL] [Abstract][Full Text] [Related]
9. Extended-release naltrexone for youth with opioid use disorder.
Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
[TBL] [Abstract][Full Text] [Related]
10. Injectable pharmacotherapy for opioid use disorders (IPOD).
Farabee D; Hillhouse M; Condon T; McCrady B; McCollister K; Ling W
Contemp Clin Trials; 2016 Jul; 49():70-7. PubMed ID: 27282118
[TBL] [Abstract][Full Text] [Related]
11. Extended-release naltrexone opioid treatment at jail reentry (XOR).
McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
[TBL] [Abstract][Full Text] [Related]
12. Extended-release injectable naltrexone for opioid use disorder: a systematic review.
Jarvis BP; Holtyn AF; Subramaniam S; Tompkins DA; Oga EA; Bigelow GE; Silverman K
Addiction; 2018 Jul; 113(7):1188-1209. PubMed ID: 29396985
[TBL] [Abstract][Full Text] [Related]
13. Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts.
Chatterjee A; Weitz M; Savinkina A; Macmadu A; Madushani RWMA; Potee RA; Ryan D; Murphy SM; Walley AY; Linas BP
JAMA Netw Open; 2023 Apr; 6(4):e237036. PubMed ID: 37058306
[TBL] [Abstract][Full Text] [Related]
14. Extended-release naltrexone for opioid use disorder started during or following incarceration.
Lincoln T; Johnson BD; McCarthy P; Alexander E
J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
[TBL] [Abstract][Full Text] [Related]
15. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
16. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
[TBL] [Abstract][Full Text] [Related]
17. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
[TBL] [Abstract][Full Text] [Related]
18. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
[TBL] [Abstract][Full Text] [Related]
19. Attitudes toward extended-release naltrexone treatment for opioid use disorder among African Americans.
Rigg KK
Drug Alcohol Depend; 2024 Apr; 257():111260. PubMed ID: 38492256
[TBL] [Abstract][Full Text] [Related]
20. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial.
Lee JD; Friedmann PD; Boney TY; Hoskinson RA; McDonald R; Gordon M; Fishman M; Chen DT; Bonnie RJ; Kinlock TW; Nunes EV; Cornish JW; O'Brien CP
Contemp Clin Trials; 2015 Mar; 41():110-7. PubMed ID: 25602580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
